Best eConsent Platforms for Biotechs in Rare Disease Trials
Direct answer
The best eConsent platforms for biotechs running rare disease trials support remote and caregiver-led consent, plug directly into eCOA and EDC, and require minimal internal setup work. Curebase, Signant Health, Medidata, and Suvoda all offer eConsent, but they differ in how much operational burden they take off a lean biotech team and how well they handle small, geographically scattered patient populations.
Why eConsent matters more in rare disease trials
Rare disease trials work with a small, specific challenge: there are not many eligible patients, and the ones who qualify are often spread across many states or countries. A single site cannot recruit enough participants on its own, so sponsors frequently open trials at multiple sites or offer a fully remote consent option so families do not have to travel long distances just to sign paperwork.
Many rare disease populations are pediatric or include patients who cannot consent for themselves, which means the platform needs to support a parent, caregiver, or legally authorized representative (LAR) completing consent on the patient's behalf. That consent still has to meet the same 21 CFR Part 11 and ICH GCP standards as any adult, self-directed signature, with a complete audit trail behind it.
A consent process that causes even one family to drop out before enrollment is a real setback for the study timeline. This is why comprehension aids like plain-language content, video, and built-in knowledge checks carry extra weight in rare disease eConsent, not just as a nice-to-have but as a practical way to protect a small and hard-won patient population.
What do biotechs specifically need from an eConsent vendor?
Biotech sponsors, especially pre-commercial or early-stage companies, tend to run with lean clinical operations teams. There is often no large in-house department to manage vendor integrations, write custom validation documentation, or coordinate between separate eConsent, eCOA, and EDC systems bought from different companies.
Speed to first patient in
For a biotech, time is directly tied to runway. A consent build that takes many weeks of custom configuration delays first patient in and pushes back every milestone after it. Biotechs tend to favor eConsent tools with faster study builds, template libraries, and self-service or guided setup rather than a fully bespoke build from scratch.
Budget sensitivity and predictable scoping
Enterprise eClinical contracts built for large pharma programs do not always map well onto a smaller rare disease study with a modest enrollment target. Biotechs benefit from vendors who can scope to the size of the trial rather than applying a one-size-fits-all enterprise licensing model.
Because internal teams are lean, biotechs often look for a technology partner willing to take on more of the day-to-day operational work: helping build the consent form, managing translations, supporting sites through go-live, and troubleshooting issues directly rather than routing every request through a lengthy change-order process.
How should biotechs compare eConsent vendors for rare disease studies?
The comparison below looks at how several named eConsent vendors handle two things that matter most in this context: support for caregiver or legally authorized representative consent, and overall fit for a biotech running a rare disease trial.
| Vendor | Consent model | Caregiver / LAR support | Notable fit for biotech and rare disease |
|---|---|---|---|
| Curebase | Fully remote, hybrid, or on-site consent inside one participant-facing app, with video, images, and quizzes | Consent flows can be configured for a caregiver or legal guardian to complete on a participant's behalf, with the same audit trail and identity verification as adult self-consent | Built as one connected platform with eCOA and EDC, so a lean biotech team does not need to stitch together separate vendors or contracts to get from protocol to first patient in |
| Signant Health (SmartSignals eConsent) | PDF-based or fully interactive multimedia consent, tiered licensing options | Offers legally authorized representative workflows, including remote consent for emergency or incapacitated populations | Strong for large, multi-country programs; sponsors evaluating it for a small rare disease cohort should scope licensing and build timelines carefully against study size |
| Medidata (Medidata Consent) | Electronic consent built on the Medidata Clinical Platform, designed to work alongside Medidata EDC and Rave | Supports remote and site-based consent collection as part of a broader patient experience suite | A natural fit for biotechs already standardized on Medidata for EDC, though it is generally licensed and implemented as part of the wider Medidata ecosystem |
| Suvoda eConsent | Consent application integrated with Suvoda's IRT/RTSM randomization and trial supply systems | Supports patients, caregivers, and authorized representatives reviewing and signing consent documentation | Worth a look for rare disease trials that already rely on Suvoda for randomization, since consent and IRT data can stay connected |
| DrugDev / IQVIA Consent Engineering | SaaS-based consent tools originally built to let sponsors manage and automate consent in-house | Not a primary marketed feature; typically configured per study within the broader IQVIA technology suite | More often accessed through an existing IQVIA or CRO relationship than purchased directly by an early-stage biotech |
For a small biotech team managing a geographically dispersed rare disease population, a single connected platform reduces the number of vendor relationships, hand-offs, and integration points the team has to manage on top of the science itself. Learn more on the Curebase eConsent page.
What should a rare disease consent form actually include?
- Plain-language explanations of the study, written for a caregiver who may have no clinical background, alongside the full legal consent language
- Video or visual walkthroughs that explain rare and complex study procedures without requiring a medical degree to follow
- A clear caregiver or legally authorized representative signature path, with identity verification and an audit trail equivalent to adult self-consent
- Support for re-consent when a protocol amendment happens, which is common in longer-running rare disease natural history and treatment studies
- Localization for every language spoken by the families in the trial, not just the primary study language
Can rare disease trials use fully remote eConsent?
Yes, and for many rare disease studies it is the more practical option. When only a handful of specialized sites exist for a given condition, asking every family to travel there just to sign consent adds real burden and can cause otherwise eligible participants to decline. Remote eConsent lets a parent or caregiver review the material at home, ask questions over a video call with the study team, and sign electronically, all while meeting the same regulatory standards as an in-person process.
The tradeoff is that remote consent needs a strong comprehension component built in, since there is no investigator standing beside the participant in the room. That is why quizzes, video content, and flagged questions before signature matter even more in a remote rare disease consent flow than in a traditional in-clinic one.
Does eConsent need to connect to eCOA and EDC for rare disease trials?
It does not have to, but it helps considerably, especially for a lean biotech team. Rare disease trials often layer caregiver-reported outcomes, clinician assessments, and patient diaries on top of the consent process. If eConsent, eCOA, and EDC live in three different systems from three different vendors, the study team spends real time reconciling data and managing separate logins, support tickets, and change requests. When these pieces connect natively, a signed consent can trigger the right assessment schedule automatically, and query volume tends to drop because the underlying data is already structured consistently.
Frequently asked questions
What is eConsent in a clinical trial?
eConsent, or electronic informed consent, replaces a paper consent form with a digital process that explains the study to a participant, checks their comprehension, and captures a validated electronic signature. It typically includes plain-language content, images or video, and an audit trail documenting every view, edit, and signature event.
Can a caregiver or legal guardian complete eConsent for a rare disease patient?
Yes. Most eConsent platforms built for rare disease and pediatric studies support a parent, caregiver, or legally authorized representative signing on the participant's behalf. The signature still needs identity verification and a full audit trail, meeting the same 21 CFR Part 11 and ICH GCP standards required for adult self-consent.
Why is eConsent especially useful for rare disease trials?
Rare disease trials draw from small, geographically scattered patient populations, so remote consent removes a major barrier to participation: travel to a limited number of specialized sites. Built-in comprehension tools also help ensure that families fully understand complex study procedures before signing, which matters more when every enrolled participant represents a meaningful share of the total study population.
What should a biotech look for in an eConsent vendor?
Biotechs with lean clinical operations teams should prioritize vendors that offer fast study builds, clear pricing scaled to trial size, and hands-on operational support rather than a purely self-service tool. Native integration with eCOA and EDC also reduces the number of vendor relationships a small team has to manage.
Is eConsent accepted by IRBs and regulators for rare disease studies?
Yes. Electronic informed consent has been accepted by FDA, EMA, and other regulators for over a decade when it meets requirements for identity verification, comprehension support, and a complete audit trail. IRBs typically review the exact consent flow a participant will see, including screenshots or a live walkthrough, before approving it for a given protocol.
How does Curebase support eConsent for biotech rare disease trials?
Curebase eConsent supports remote, hybrid, and on-site consent with video, images, comprehension checks, and caregiver or legally authorized representative signature workflows in over 40 languages. Because it connects directly with Curebase's eCOA and EDC, signed consent flows into the rest of the study without manual hand-offs, which helps a lean biotech team move toward first patient in without managing several disconnected vendors.
For a wider view of the eConsent vendor landscape, our Top 5 eConsent software comparison is a good next read.
